undamentalytics Newsletter
Sign in

Caribou Biosciences, Inc. income statement

In fiscal 2025, Caribou Biosciences, Inc. reported revenue of $11.2m, up 11.7% on the year before, operating income of −$148m (a -1329.4% margin) and net income of −$148m, or −$1.59 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue612101434101110
Research and development2434528211213010986
General and administrative1614243838463834
Operating income−34−36−67−106−116−167−148−109
Interest expense000—————
Income before tax−31−36−67−99−102−149−149—
Income tax−8−2000−0−1—
Net income−23−34−67−99−102−149−148−103
Diluted EPS−$1.40−$2.00−$1.05−$1.64−$1.38−$1.65−$1.59−$1.08
Diluted shares (average)17m17m63m61m74m90m93m96m
EBITDA−34−35−66−105−113−163−145−107

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: CRBU vs IRDCRBU vs RLAYCRBU vs HYFT

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Caribou Biosciences, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Caribou Biosciences, Inc.